Xentuzumab

DB14871InvestigationalProtein Based Therapies

Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).

Mechanism: Pharmacologically active on Insulin-like growth factor 1 and Insulin-like growth factor 2
Curator reviewed
Code names: BI 836845

Resolves to

Compound

UNIIX86Z1O656GCAS1417158-65-6

Targets

P05019IGF1P01344IGF2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Xentuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account